TheFly published on November 26, 2025, that Chardan kept its buy recommendation on CRISPR Therapeutics AG (NASDAQ:CRSP) while ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

We came across a bullish thesis on CRISPR Therapeutics AG (CRSP) on Two Natural Cap’s Substack. In this article, we will summarize the bulls’ thesis on CRSP. CRISPR Therapeutics AG (CRSP)’s share was ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

According to Benzinga Pro, CRISPR Therapeutics AG's peer group average for short interest as a percentage of float is 14.28%, ...

RGA Investment Advisors, an investment management company, has released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The second quarter-end figures concealed ...

CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.29 per share versus the Zacks Consensus Estimate of a loss of $1.47. This compares to a loss of $1.49 per share a year ago. These ...

Congress Wealth Management LLC DE purchased a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional ...

Hello, everyone. My name is Mitchell Kapoor. I'm a senior biotech analyst at H.C. Wainwright. Today, I have the pleasure of welcoming CRISPR Therapeutics. And from the company, Raj Prasad, CFO, is ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $38.54, marking a -1.76% move from the previous day. This change lagged the S&P 500's daily gain of 1.67%. Elsewhere, the Dow saw ...